Status:

COMPLETED

The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Lead Sponsor:

Centocor Ortho Biotech Services, L.L.C.

Conditions:

Arthritis, Rheumatoid

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

The purpose of the study was to evaluate the ability of a maintenance dosage regimen of infliximab to achieve and sustain at least 40% improvement from baseline in the total joint count in patients wi...

Detailed Description

Rheumatoid arthritis (RA) is a chronic autoimmune disorder of unknown etiology that occurs in approximately one percent of the population. Current therapy for RA comprises non-steroidal anti-inflammat...

Eligibility Criteria

Inclusion

  • Previous diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al., 1988)
  • patients must have a minimum of 8 tender and 4 swollen joints with disease diagnosed at least 3 months prior to screening
  • patients must have been using oral or parenteral MTX for at least the previous 3 months, and at a stable dose of 7.5 to 25 mg per week for at least the previous 1 month
  • women of childbearing potential must test negative for pregnancy and be using adequate birth control measures
  • patients must have a documented purified protein derivative (PPD) skin test performed at prescreening.

Exclusion

  • Patients who have received any prior treatment with infliximab or with any other therapeutic agent targeted at reducing tumor necrosis factor (TNF) (e.g., etanercept, pentoxifylline or thalidomide) within the previous 3 months
  • patients who are incapacitated
  • history of infected joint prosthesis within the previous 5 years
  • patients with a concomitant diagnosis of congestive heart failure (CHF), history of or known malignancy within the previous 5 years, cases of active or latent tuberculosis (TB), acute or chronic serious infections within the past 3 months
  • known substance abuse (drug or alcohol) within the previous 3 years

Key Trial Info

Start Date :

December 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2003

Estimated Enrollment :

210 Patients enrolled

Trial Details

Trial ID

NCT00246064

Start Date

December 1 2001

End Date

November 1 2003

Last Update

May 19 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.